Rhabdomyolysis Incidence with Vancomycin
Rhabdomyolysis is not a recognized or reported adverse effect of vancomycin therapy. The FDA-approved drug label for vancomycin does not list rhabdomyolysis as an adverse reaction, and major clinical practice guidelines do not identify it as a concern 1.
Known Adverse Effects of Vancomycin
The established toxicities associated with vancomycin include:
Nephrotoxicity (Most Common Serious Adverse Effect)
- Acute kidney injury (AKI) is the primary concern with vancomycin, occurring in approximately 4.9-15% of patients depending on the population and diagnostic criteria used 2, 3
- Risk increases with higher serum levels/AUC exposure, concomitant nephrotoxic drugs (especially aminoglycosides and piperacillin-tazobactam), pre-existing renal impairment, and prolonged therapy 1, 4
- Interstitial nephritis has also been reported 1
Infusion-Related Reactions
- Red man syndrome (flushing, hypotension, pruritus) occurs with rapid infusion
- Prevented by infusing over ≥60 minutes 1
Ototoxicity
- Rare, mostly in patients with excessive doses, underlying hearing loss, or concurrent ototoxic agents 1
Hematologic Effects
- Reversible neutropenia (typically after >1 week or >25g total dose)
- Rare thrombocytopenia 1
Severe Dermatologic Reactions
- Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome (rare) 1
Important Clinical Distinction
While one case series described a "precipitous rise in serum creatinine" with vancomycin that was initially concerning for rhabdomyolysis, overt rhabdomyolysis was explicitly absent in all cases 5. The steep creatinine elevation was attributed to direct tubular toxicity rather than muscle breakdown, and creatine kinase levels were not elevated.
Monitoring Recommendations
Based on IDSA guidelines, monitor for nephrotoxicity rather than rhabdomyolysis 6:
- Obtain baseline creatinine and monitor renal function regularly
- Target trough concentrations of 15-20 mg/L for serious MRSA infections
- Use AUC-guided dosing when available for optimal safety 6
- Avoid combining with other nephrotoxins when possible
Bottom line: Rhabdomyolysis is not an established complication of vancomycin therapy. The primary toxicity concern is nephrotoxicity, which requires appropriate dosing, therapeutic monitoring, and avoidance of concomitant nephrotoxic agents.